NLS drug-2

The two companies have announced topline results from the follicular lymphoma (FL) cohort of the EPCORE NHL-1 clinical trial evaluating epcoritamab, an investigational T-cell engaging bispecific antibody administered subcutaneously. The study cohort includes 128 adult patients with relapsed/refractory follicular lymphoma (FL) who received at least two prior lines of systemic therapy. 70.3 percent of patients […]

Novo Nordisk has announced data from the ONWARDS 1 and 3 trials evaluating investigative once-weekly basal insulin icodec. The data showed the studies met their primary endpoints, while reducing injections from seven to one per week, compared with once-daily basal insulin. Additionally, data from the ONWARDS 1 and 3 studies demonstrated that more insulin-naïve adults […]

FluoGuide has announced positive interim results from the phase IIa trial of its lead product FG001 in head & neck cancer. FG001 was shown to illuminate tumors in all of the patients and it was also shown to light up tumors in 100% of the patients, reports the company. “We are pleased to report another […]

Ultimovacs has announced overall survival (OS) data from the cohort 2 in the UV1-103 Phase I clinical trial in malignant melanoma. All patients in cohort 2 who were alive at the 2-year follow-up, remain alive at the 3-year follow-up, reports the company in a press release. The UV1-103 study The UV1-103 study evaluates Ultimovacs’ universal […]

Zerion Pharma has announced the publication of joint experimental work on its Dispersome technology in the International Journal of Pharmaceutics and Pharmaceutical Research, two peer-reviewed papers. The work behind the publications originated from two partnership projects, one with Bayer AG and one with Novartis Pharma AG. The former can be accessed here and showcases the […]

Ultimovacs has announced the topline results of  NIPU, an investigator-initiated Phase II trial in patients indicated for second-line treatment of malignant pleural mesothelioma (MPM). Based on central review, the study did not meet the primary endpoint of PFS. Investigator assessment of the primary endpoint, a pre-defined supportive analysis, showed a statistically significant positive PFS benefit […]